2020 Guide to Patient Support Services


Pharmacyclics, an AbbVie Company, together with Janssen Biotech, created a unique set of patient support programs called YOU&i Support Program. This is a personalized program that helps patients to access Imbruvica (ibrutinib), a Bruton kinase inhibitor; find affordability support options; and sign up for information and resources to support them during their treatment (Table).


This program will:

  • Contact patients’ insurance provider to help understand benefits
  • Find options to help patients afford their treatment
  • Provide educational information
  • Offer nurse call support and respond to questions.

YOU&i Instant Savings Program

For commercially insured patients, Pharmacyclics and Janssen Biotech offer the YOU&i Instant Savings Program to help with private insurance copay, deductible, and coinsurance costs for Imbruvica. This program enables eligible patients with commercial insurance to pay a $10 monthly co­pay for Imbruvica, regardless of income level.


To be eligible for the YOU&i Instant Savings Program, patients must:

  • Reside in the United States or Puerto Rico
  • Have been prescribed Imbruvica
  • Have commercial insurance
  • Not be enrolled in federal- or state-subsidized healthcare programs that cover prescription drugs, including Medicare Part D, Medicare Advantage Plan, Medicaid, TRICARE, or any other federal or state healthcare plan, including pharmaceutical assistance programs.

Independent Foundations

For uninsured patients, the Janssen affiliated Johnson & Johnson Patient Assistance Foundation, which is an independent, nonprofit organization, may offer assistance with accessing Imbruvica for eligible patients who qualify based on financial need, such as an income requirement of 600% of the federal poverty level.


Enrollment for the YOU&i Support Program can be completed online or calling 877-877-3536.


Patient support programs

Imbruvica (ibrutinib)
Treatment of adults with mantle-cell lymphoma after ≥1 therapies; treatment of adults with CLL or with SLL, including CLL or SLL with 17p deletion; first-line treatment of adults with CLL or SLL, in combination with obinutuzumab; treatment of adults with Waldenström’s macroglobulinemia; treatment of marginal-zone lymphoma in adults who require systemic therapy, after ≥1 anti-CD20-based therapy; treatment of adults with chronic graft-versus-­host disease, after failure of ≥1 lines of systemic therapy
Patient support programs

CLL indicates chronic lymphocytic leukemia; SLL, small lymphocytic lymphoma.

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: